Novo Nordisk announced Monday that in two closely watched studies, an oral version of semaglutide — the active ingredient in weight loss drugs — failed to help slow the progression of Alzheimer’s.

Novo Nordisk is undervalued and oversold, despite strong fundamentals and a promising pipeline. The market's reaction to ...

Dow Jones Top Company Headlines at 1 PM ET: Kohl's Shares Rocket Higher as Retailer Lifts Outlook | Best ... The stock soared 35% in a meme-like rally after the department-store chain said its ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

Medicare will announce negotiated prices for 15 high-cost drugs, impacting over 67 million beneficiaries. The Inflation ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs ...

Dr. Terry Dubrow and Heather Dubrow explain one of the NSFW side effects related to men who take Ozempic or other semaglutide ...

Novo Nordisk GLP-1 fails to slow Alzheimer's in phase 3 trials involving 3,808 adults with mild cognitive impairment or dementia.

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

The U.S. stock market is rising again on Monday, for now at least, ahead of a week with shortened trading because of the Thanksgiving holiday.

Novo Nordisk’s amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its efficacy could become even stronger with longer follow-up, according to analysts ...